4-ethyl-3-(3-imidazo[1,2-a]pyrazin-3-ylphenyl)-N-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]benzamide
C33H34N6O — CID 155552517
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-ethyl-3-(3-imidazo[1,2-a]pyrazin-3-ylphenyl)-N-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]benzamide
4-ethyl-3-(3-imidazo[1,2-a]pyrazin-3-ylphenyl)-N-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]benzamide (PubChem CID 155552517) has the molecular formula C33H34N6O and a molecular weight of 530.68 g/mol. Its IUPAC name is 4-ethyl-3-(3-imidazo[1,2-a]pyrazin-3-ylphenyl)-N-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]benzamide.
Molecular Properties
| Compound Name | 4-ethyl-3-(3-imidazo[1,2-a]pyrazin-3-ylphenyl)-N-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]benzamide |
|---|---|
| PubChem CID | 155552517 |
| Molecular Formula | C33H34N6O |
| Molecular Weight | 530.68 g/mol |
| Exact Mass | 530.28 |
| IUPAC Name | 4-ethyl-3-(3-imidazo[1,2-a]pyrazin-3-ylphenyl)-N-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]benzamide |
| SMILES | CCc1ccc(C(=O)Nc2cccc(CN3CCN(C)CC3)c2)cc1-c1cccc(-c2cnc3cnccn23)c1 |
| InChI | InChI=1S/C33H34N6O/c1-3-25-10-11-28(33(40)36-29-9-4-6-24(18-29)23-38-16-14-37(2)15-17-38)20-30(25)26-7-5-8-27(19-26)31-21-35-32-22-34-12-13-39(31)32/h4-13,18-22H,3,14-17,23H2,1-2H3,(H,36,40) |
| InChIKey | RUDJLSWOUHMLOU-UHFFFAOYSA-N |
| XLogP | 5.63 |
| TPSA | 65.77 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 40 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 530.68 |
| LogP ≤ 5 | 5.63 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155552517 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.